• Douglas J Van Daele, Kellie L Bodeker, and Douglas K Trask.
• University of Iowa, Iowa City, Iowa, USA douglas-van-daele@uiowa.edu.
• Ann. Otol. Rhinol. Laryngol. 2016 Oct 1; 125 (10): 785-800.

ObjectivesCelecoxib is a cyclooxygenase-2-specific inhibitor indicated to treat acute pain and pain secondary to osteoarthritis and rheumatoid arthritis. Surgical models of acute pain have demonstrated superior pain relief to placebo. The objective of this study was to test the safety and efficacy of celecoxib for pain relief after tonsillectomy compared to placebo.MethodsAdult subjects were randomized to 200 mg celecoxib versus placebo with a loading dose the night before surgery then twice daily for 10 days. Subjects were instructed to supplement the study drug with hydrocodone/acetaminophen liquid or acetaminophen for pain as needed. Subjects completed a daily diary regarding their pain, nausea, vomiting, diet, and activity.ResultsSeventeen subjects enrolled. Intraoperative blood loss was similar between groups, and no subject had postoperative bleeding. Three patients returned to the emergency department for treatment, and 2 patients could not complete the diaries, all in the placebo group. Subjects in the placebo group required statistically significant (P < .05) higher doses of narcotic and acetaminophen to control pain. Pain and diet rating scores were slightly better in the celecoxib group compared to placebo.ConclusionsIn this small cohort, celecoxib reduced postoperative narcotic and acetaminophen requirements compared to placebo without complications.© The Author(s) 2016.

32 keywords...

hide…